New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 21, 2012
09:59 EDTNRGM, HTWR, AMX, EXXI, HRL, EV, STJ, HPQ, CBSH, FANGOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: America Movil (AMX) downgraded to Neutral from Buy at Citigroup... Commerce Bancshares (CBSH) downgraded to Underweight from Equal Weight at Morgan Stanley... Eaton Vance (EV) downgraded to Sell from Neutral at Citigroup... HeartWare (HTWR) downgraded to Market Perform from Outperform at Wells Fargo... Hewlett-Packard (HPQ) downgraded to Sector Perform from Outperform at RBC Capital... Hewlett-Packard (HPQ) downgraded to Underperform from Neutral at Mizuho... Hormel Foods (HRL) downgraded to Underperform from Outperform at CLSA... Inergy Midstream (NRGM) downgraded to Neutral from Outperform at RW Baird... St. Jude Medical (STJ) downgraded to Market Perform from Outperform at Wells Fargo.... Energy XXI (EXXI) initiated with a Buy at Ladenburg... Diamondback Energy (FANG) intiated with an Add at Capital One.
News For AMX;CBSH;EV;HTWR;HPQ;HRL;NRGM;STJ;EXXI;FANG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
July 21, 2015
12:40 EDTSTJ, HTWRSt. Jude in talks to acquire Thoratec, Bloomberg reports
St. Jude Medical (STJ) is in talks to acquire Thoratec (THOR), Bloomberg reports, citing people familiar with the situation. Talks are ongoing and could still fall apart as no deal has been reached, Bloomberg adds. Thoratec shares spiked early in today's session, but a catalyst for the move was unclear before the Bloomberg report. Shares of the medical device maker focused on advanced heart failure patients are up $9.52 to $58.33 in midday trading. Its close competitor HeartWare (HTWR) is now up $5.53 to $84.70. Shares of St. Jude are up 4 to $76.61. Reference Link
12:33 EDTHTWR, STJThoratec jumps after Bloomberg report of St. Jude buyout talks
Subscribe for More Information
12:29 EDTSTJSt. Jude Medical in talks to acquire Thoratec, Bloomberg reports
Subscribe for More Information
12:21 EDTSTJOn The Fly: Top stock stories at midday
Subscribe for More Information
10:20 EDTHTWR, STJCatalyst behind Thoratec spike higher unclear
The catalyst behind the spike higher in shares of Thoratec (THOR) is unclear to traders and investors. The medical device maker focused on advanced heart failure patients rose as high $62.05 in early trading and its shares remain up 11%, or $5.48, to $54.29. Some vague takeover chatter surfaced, with St. Jude Medical (STJ) as the speculated buyer, but buyout rumors are often the "go-to" reason when stocks spike. Often the moves on rumors are less substantial than Thoratec's spike today. The company's close competitor HeartWare (HTWR) is not seeing any unusual trading thus far today, falling 36c to $78.81 in early trading.
10:01 EDTEVOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:58 EDTHTWRThoratec jumps 14% to $55.82 in early trading
Subscribe for More Information
07:52 EDTHPQHP announces renewable energy agreement with SunEdison
Subscribe for More Information
06:19 EDTHPQSilicon Valley giants side with Samsung in battle with Apple, InsideSources says
Subscribe for More Information
06:12 EDTEVEaton Vance downgraded to Neutral from Outperform at Credit Suisse
Subscribe for More Information
July 20, 2015
08:32 EDTSTJSt. Jude Medical receives FDA approval for MR-conditional 5-column paddle lead
Subscribe for More Information
07:10 EDTHTWRHeartWare begins its MVAD System CE Mark international clinical trial
Subscribe for More Information
06:31 EDTAMXAmerica Movil's tower spinoff slated for Q3, Reuters reports
Subscribe for More Information
July 16, 2015
19:41 EDTAMXAmerica Movil CEO pledges $6B investment in Mexican network, Reuters says
Subscribe for More Information
08:34 EDTSTJSt. Jude Medical receives FDA approval for spinal cord stimulation trial system
St. Jude Medical (STJ) announced it received FDA approval of the Invisible Trial System. The system, which received CE Mark in June 2015, is fully wireless and leverages Apple (AAPL) technology for both the patient and physician controllers. The system is designed to provide patients a more improved and discreet spinal cord stimulation, or SCS, trial experience. "Patients undergoing SCS trials consistently tell us about challenges they find in navigating the SCS trial system, from programming the device, to discomfort from the programming cables, to management of both issues. These hindrances may impede the integration of the technology into their daily activities, which shifts their focus away from evaluating the effectiveness of SCS therapy,” said pain specialist Dr. Jason E. Pope, president of Summit Pain Alliance in Santa Rosa, California. “By providing a discreet trial system, St. Jude Medical will help patients focus more on their potential pain relief and functional improvements, and less about the burdens common to traditional trial systems.”
July 15, 2015
10:59 EDTHTWRHeartWare drops after analyst cuts target to $60
Shares of HeartWare are moving lower after Northland analyst Suraj Kalia cut his price target for the name to $60 from $70. The company manufactures implantable heart pumps for patients suffering from advanced heart failure. Recent sheep data for the company's MVAD Pump with new impeller design show a "flowrate profile that seems to be on a downtrend over time," Kalia told investors this morning in a research note. The incomplete data raise more questions, the analyst contends. The MVAD Pump is a continuous axial flow pump, one-third the size of HeartWare's current heart pump, HVAD, according to the company. Kalia believes the MVAD will be more "problematic in patient management" than the HVAD over the long term. The analyst has an Underperform rating on HeartWare, Northland's sell rating equivalent. Shares of medical device company are down $2.22 to $71.22 in morning trading. Its peer Thoratec (THOR) is up 16c to $46.69.
10:01 EDTCBSHOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AGCO (AGCO) upgraded to Market Perform from Underperform at Wells Fargo... Anglo American (AAUKY) upgraded to Outperform from Neutral at Credit Suisse... Avis Budget (CAR) upgraded to Buy from Hold at Deutsche Bank... Brookfield Renewable (BEP) upgraded to Neutral from Underperform at Credit Suisse... CSX (CSX) upgraded to Outperform from Sector Perform at RBC Capital... Centene (CNC) upgraded to Buy from Hold at Jefferies... Commerce Bancshares (CBSH) upgraded to Market Perform at Raymond James... Entegris (ENTG) upgraded to Buy at Craig-Hallum... Guess (GES) upgraded to Market Perform from Underperform at Telsey Advisory... Hertz (HTZ) upgraded to Buy from Hold at Deutsche Bank... Iberdrola (IBDRY) upgraded to Buy from Hold at Societe Generale... Liberty Global (LBTYA) upgraded to Conviction Buy from Buy at Goldman... LinkedIn (LNKD) upgraded to Overweight from Equal Weight at Barclays... Lonmin (LNMIY) upgraded to Neutral from Sell at Goldman... Navient (NAVI) upgraded to Overweight from Equal Weight at Barclays... NetApp (NTAP) upgraded to Sector Weight from Underweight at Pacific Crest... Omnicom (OMC) upgraded to Outperform from Market Perform at Wells Fargo... PTC Therapeutics (PTCT) upgraded to Overweight from Neutral at JPMorgan... Panera Bread (PNRA) upgraded to Overweight from Underweight at Piper Jaffray... Primerica (PRI) upgraded to Strong Buy from Market Perform at Raymond James... Sands China (SCHYY) upgraded to Overweight from Equal Weight at Barclays... Seagate (STX) upgraded to Buy at Craig-Hallum... Western Digital (WDC) upgraded to Buy from Hold at Craig-Hallum... Wolseley (WOSYY) upgraded to Overweight from Neutral at JPMorgan.
08:57 EDTHTWRLeerink medical devices analyst holds an analyst/industry conference call
Subscribe for More Information
08:49 EDTHTWRHeartWare price target lowered to $60 from $70 at Northland
Northland lowered its price target for HeartWare to $60 saying the latest sheep study publication for the MVAD with new impeller design raises more questions. The firm believes that over the long term, MVAD will be more problematic in patient management than the HVAD. It keeps an Underperform rating on HeartWare.
06:34 EDTCBSHCommerce Bancshares upgraded to Market Perform at Raymond James
Raymond James upgraded Commerce Bancshares to Market Perform from Underperform following the Q2 beat citing valuation.
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use